Study design and ethics
This prospective RCT was conducted after approval by the Ethics Committee of our hospital (YX2021-124) on December 30, 2021. The study was prospectively registered in the Chinese Clinical Trial Registry (http://www.chictr.org.cn, ChiCTR2200056421) on 05/02/2022. The study was conducted in accordance with the Consolidated Standards of Reporting Trials (CONSORT) criteria [6] and in compliance with the Helsinki Declaration. Written informed consent was obtained from all participants.
Participants
All of the patients were scheduled for hip surgery due to fractures and screened to assess their eligibility. The inclusion criteria were patients aged ≥ 60 years with physical status grades from I–III based on the American Society of Anesthesiologists (ASA). The exclusion criteria were known allergies to any of the anesthesia drugs used in this study, a history of hip surgery on the current operation side, a body mass index > 30 kg∙m− 2, severe hepatic or renal dysfunction, contraindications for regional anesthesia, atrioventricular, intra-ventricular or sinoatrial block, bradyarrhythmia with a baseline rate < 50 beats/min, uncontrolled hypertension, severe pulmonary hypertension, preoperative oxygen saturation measured by pulse oximetry (SpO2) < 95%, a history of mental disorders and severe visual or auditory disorders.
Randomization And Blinding
Patients were randomized to receive opioid-free anesthesia (Group OFA) or opioid-balanced anesthesia (Group CON) at a ratio of 1:1 using computer software. An assistant who was not involved in the study prepared the randomization list and concealed group assignments in consecutively numbered, sealed, opaque envelopes. A nurse unaffiliated with patient care opened the envelopes shortly before surgery and prepared the study medication. The anesthesiologist in charge of the patient administered the medication and adjusted the depth of anesthesia intraoperatively. The nurse and the anesthesiologist did not participate in the following assessment at any time. Thereafter, the nurses who provided postoperative care, the surgeons, investigators, and outcome assessors were blinded to the group allocations and did not have access to randomization until data analysis was complete.
Procedures
After arrival in the preoperative holding area with standard monitoring, intravenous access was established and premedication (midazolam 0.02 mg kg− 1 and sufentanil 0.1 µg kg− 1) was administered to every patient. Radial artery catheterization was performed for invasive arterial blood pressure monitoring. All patients received a preoperative fascia iliaca block with 25 ml of 0.25% ropivacaine. Thereafter, the patients were transferred to the operating room and received general anesthesia. All patients received intravenous dexamethasone 8 mg to prevent postoperative nausea and vomiting (PONV). Parecoxib sodium (0.8 mg∙kg− 1) was administered after induction as prophylactic analgesia.
Patients in the OFA group received dexmedetomidine at a loading dose of 0.7 µg∙kg− 1 over 10 min before induction. Anesthesia induction and tracheal intubation were performed using intravenous esketamine 0.35–0.5 mg∙kg− 1, etomidate 0.2–0.3 mg∙kg− 1, and cisatracurium 0.2 mg∙kg− 1. Maintenance of anesthesia was achieved by continuous infusion of dexmedetomidine 0.1 µg∙kg− 1∙h− 1 and esketamine 0.25 mg∙kg− 1∙h− 1 until the beginning of wound closure, and propofol 2–10 mg∙kg− 1∙h− 1 was terminated at the end of surgery. Patients in the CON group received intravenous sufentanil 0.2–0.3 µg∙kg− 1, etomidate 0.2–0.3 mg∙kg− 1, and cisatracurium 0.2 mg∙kg− 1 for anesthesia induction and tracheal intubation, and continuous infusion of remifentanil 6–15 µg∙kg− 1∙h− 1 combined with propofol 2–10 mg∙kg− 1∙h− 1 for anesthesia maintenance which was terminated at the end of surgery (Fig. 1). The depth of anesthesia was adjusted to maintain a bispectral index target in the range of 40–60.
At a proper depth of anesthesia, an intermittent bolus of urapidil was administered if the MAP was > 90 mm Hg or > 20% of the baseline values. Esmolol was administered if the HR was > 120 bpm. In hypotensive cases, defined as a MAP < 60 mmHg or a reduction of > 20% of baseline values, additional fluid and an intermittent bolus of ephedrine or phenylephrine were administered. Atropine was given in cases of severe bradycardia (HR < 50 bpm). The dosage of vasoactive agent was at the discretion of the anesthesiologist.
All patients were transferred to the anesthesia intensive care unit (AICU) for recovery after extubation. Oxygen therapy was performed using a nasal cannula with an oxygen inflow of 2 L∙min− 1. A nurse, blinded to the protocols, evaluated the level of sedation using the Richmond Agitation Sedation Scale (RASS) [7] and pain intensity using the visual analogue scale (VAS) score, which ranges from ‘0’ (meaning no pain) to ‘100’ (meaning worst pain imaginable). Postoperative analgesia was maintained with a tramadol infusion using a patient–controlled intravenous analgesia (PCIA) device. The PCIA device administered a 30 mg bolus dose with a 15–minute lock-time and the basal infusion rate was set to 6 mg∙h− 1. If three boluses of tramadol did not alleviate the pain or the VAS score was > 3, a fascia iliaca compartment block with 20 ml of ropivacaine 0.25% was performed as rescue analgesia. When the SpO2 was < 95%, oxygen was administered through a mask with an inflow of 5 L∙min− 1.
Patients were followed during the first 48 h after the operation. Adverse events including PONV, hypoxemia (defined as a SpO2 level < 95% with a need for oxygen supplementation) [8], postoperative ileus (defined as an absence of flatus or stools), urinary retention (defined as the inability to void with bladder distention and need of catheterization), delirium (measured twice daily using the Confusion Assessment Method) [9] were recorded. Sleep quality during the first postoperative night was evaluated using the Richards-Campbell Sleep Questionnaire [10]. Quality of life was assessed using the VAS score of the EuroQol 5 Dimension 5 Level (EQ-5D-5L) [11] 30 days after surgery by a telephone interview.
Outcomes
The primary outcome was the incidence of composite adverse events occurring within 48 hours after surgery. The secondary endpoints included pain scores at rest and in motion during the first 48 h postoperatively, the number of patients who received nerve block for rescue analgesia, the RASS scores during the first 30 min in the AICU, the time to extubation (defined as the interval between the end of the operation and extubation), unplanned intensive care unit (ICU) admissions, sleep quality and the length of postoperative hospital stay. Safety elements included intraoperative cardiovascular events and severe postoperative complications such as cerebrovascular events, myocardial infarction, heart failure, and acute kidney injury until hospital discharge. The incidence of readmission and all-cause motality were also assessed.
Statistical Analysis
The primary outcome of this study was the incidence of postoperative anesthetic drug-related complications. We assumed a 40% incident rate for the primary outcome (10% rates of postoperative hypoxemia [12], nausea and vomiting [13] and delirium [14]; 5% rate of postoperative ileus [15] and urinary retention [16]). Our pilot data indicated a 43% incidence of adverse events in the control group (n = 21) which was close to the observations, whilst the incidence of adverse events in the opioid-free group was 19% (n = 21). A 2-sampled t-test was used for the power analysis. The required sample size was 55 patients per group with an alpha error of 0.05 and a power of 0.8 calculated using the PASS software version 15.0 (NCSS LLC). Assuming a 10% dropout rate, 60 subjects per group were considered for recruitment in this study.
All statistical analyses were performed using SPSS Statistics (version 24.0; IBM, Armonk, NY, USA). Kolmogorov–Smirnov test was performed to assess data normality. Continuous variables were expressed as means (SD) or medians (interquartile range, IQR), and inter-group differences were assessed for significance using Student t-test for normally distributed data or Wilcoxon rank sum test for nonparametric data. For categorical variables, data are presented as counts with percentages and differences were compared using a chi-square or Fisher exact test if necessary with a constructed 95% confidence interval (CI).
The effects of interventions on the outcomes of interest (pain scores, hemodynamic parameters) over time were assessed using the interaction of group and time in a repeated measures analysis of variance. The Greenhouse-Geisser correction was applied if the data violated the assumption of sphericity as determined by the Mauchly test. For measures that showed significant group by time interaction effects, a post hoc analysis was performed using Bonferroni correction. Assessments were 2-tailed, and statistical significance was set at P < 0.05.